Is Argireline FDA approved?

Argireline is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is FGF-1 FDA approved?

FGF-1 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Argireline administered in research settings?

In research settings, Argireline is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

How is FGF-1 administered in research settings?

In research settings, FGF-1 is typically administered via the topical or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Argireline vs FGF-1

Peptide Comparison

Argireline vs FGF-1

Q: What is the difference between Argireline and FGF-1?

Argireline: Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects FGF-1: Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

Both are Skin & Cosmetic peptides.

Argireline

Acetyl Hexapeptide-3

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

18 providers listed

Full Argireline profile →

FGF-1

Fibroblast Growth Factor 1

Skin & JointNot EvaluatedResearch Only

No providers listed yet

Full FGF-1 profile →

Bottom line

Argireline carries stronger published evidence (RCT, 3 key studies) than FGF-1 (RCT, 1); both are research compounds.

Quick Verdict

Argireline

Evidence

Clinical

FGF-1

Evidence

Emerging Clinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Argireline
More provider options (18 vs 0)	Argireline

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Argireline

FGF-1

Mechanism Family

Skin & Cosmetic

Half-life

N/A (topical)

—

FDA Status

not evaluated

Admin Routes

topical

topical, subcutaneous

Availability

Research Only

Providers

18 listed

None listed

Avail. Notes

Cosmetic peptide (acetyl hexapeptide-3). Sold as cosmetic ingredient by Lipotec/Sederma. Not regulated as a drug by FDA. No NDA or IND. Cosmetic anti-wrinkle ingredient only.

—

Research Evidence

Argireline

ClinicalRCT · 3 key studies · most recent 2026

FGF-1

Emerging ClinicalRCT · 1 key study · dated evidence base — most recent 2008

Research Citations

Argireline

RCT2013 · American Journal of Clinical Dermatology

The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-…

Cohort2026 · Biomater Adv

DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging.

RCT2017 · Journal of Cosmetic Dermatology

The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3: a prospective, ra…

FGF-1

RCT2008 · Molecular Therapy

Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critica…

About Argireline

Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects

Research Areas

SNARE complex (SNAP-25) competitive inhibition reducing expression line depthwrinkle reduction documented in controlled human trialstopical cosmetic application — not a systemic peptidesoftening of dynamic lines over 4–8 weeks at 5–10% concentration

About FGF-1

Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

Research Areas

wound healinghair growth supportskin repairangiogenesisfibroblast activation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Argireline

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

FGF-1

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Find Providers

Where to source these peptides

Providers offering

Argireline

18 listed

Browse directory →

Providers offering

FGF-1

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.